| Today's Big NewsApr 27, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out,register today.
|
|
| By Annalee Armstrong The writing was on the wall for Nektar and Eli Lilly’s rezpeg collaboration, but now the Big Pharma is etching it in permanent marker. Rights for the T regulatory cell stimulator treatment are now headed back to the biotech. |
|
|
|
By Nick Paul Taylor Sanofi’s first-quarter update brought bad news for drug candidates acquired in buyouts worth $8 billion, with the French drugmaker removing Ablynx and Principia Biopharma molecules from its pipeline after getting a look at clinical data. |
By Nick Paul Taylor AstraZeneca has dumped a $855 million rare disease drug candidate after chalking up a pair of phase 2 flops, despite the prospect previously hitting the mark in a much larger phase 3 trial. The drugmaker disclosed the action alongside news of the jettisoning of a nonalcoholic steatohepatitis (NASH) therapy. |
By Gabrielle Masson AbbVie is discontinuing all work in cystic fibrosis after a phase 2 flop, while also scrapping another phase 2 program in immunology. |
By James Waldron A month after being abandoned by Biogen and Novartis in quick succession, Sangamo is now laying off around 120 employees as the genomic medicines biotech refocuses on three key areas. |
By Annalee Armstrong SAB Biotherapeutics vowed to plow on through the fields with a cow-plasma-based COVID-19 treatment after the National Institutes of Health (NIH) dropped out last year. Now, the data harvest from that government-partnered study is complete and the company is pointing to secondary endpoints as signs of success. |
By Max Bayer Antiva Biosciences has closed a $53 million series E round, a rare late-stage private financing that’s set to fund the company through crucial future readouts. |
By Angus Liu Eli Lilly’s trending weight loss candidate tirzepatide has scored its second pivotal trial win, teeing up a potential FDA approval as early as late this year. |
By Angus Liu In a surprise announcement Wednesday, Bristol Myers Squibb said CEO Giovanni Caforio will end his eight-year tenure and hand the baton to chief commercialization officer Chris Boerner. |
By Andrea Park After two straight years of quarterly sales growth, that trend hasn’t yet gone out of style for Boston Scientific. |
By Joseph Keenan Greenphire, a clinical trial financial process automation company, rolled out a new digital platform and upgraded international payment tools aimed to aid sponsors, trial sites and CROs. |
By Joseph Keenan MyTomorrows, a matchmaker for patients and clinical trials, has launched a beta version of its AI-supported tool to aid physicians in finding expanded access programs for treatments. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $500 when you Register Today!
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
